Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 5

Sponsor Class

OTHER 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Breast 5Genitourinary 1

Conditions

Multiple Myeloma 5Neoplasms, Plasma Cell 4Pain 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Pamidronate × Plasma cell × Clear all
NCT00004088 2019-07-02

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
77 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00482378 2018-08-14

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Mayo Clinic

Phase 1/2 Completed
39 enrolled
Plasma cell

Multiple Myeloma, Pain, Neoplasms, Plasma Cell

NCT00083382 2015-06-24

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

University of Arkansas

Phase 2 Completed
83 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00083408 2010-07-05

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

University of Arkansas

Phase 2 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00376883 2007-01-04

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Nordic Myeloma Study Group

Phase 3 Completed
500 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡